CS Medica Resultados de beneficios anteriores
Pasado controles de criterios 0/6
CS Medica's earnings have been declining at an average annual rate of -50.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 22.5% per year.
Información clave
-50.2%
Tasa de crecimiento de los beneficios
-55.0%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 7.3% |
| Tasa de crecimiento de los ingresos | 22.5% |
| Rentabilidad financiera | -676.9% |
| Margen neto | -263.8% |
| Próxima actualización de resultados | 14 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero CS Medica. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -12 | 14 | 0 |
| 31 Mar 24 | 5 | -13 | 16 | 0 |
| 31 Dec 23 | 3 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -15 | 17 | 0 |
| 30 Jun 23 | 10 | -11 | 16 | 0 |
| 31 Mar 23 | 11 | -11 | 17 | 0 |
| 31 Dec 22 | 11 | -12 | 18 | 0 |
| 30 Sep 22 | 11 | -11 | 17 | 0 |
| 30 Jun 22 | 4 | -10 | 14 | 0 |
| 31 Mar 22 | 3 | -5 | 9 | 0 |
| 31 Dec 21 | 3 | -2 | 5 | 0 |
| 30 Sep 21 | 3 | 1 | 2 | 0 |
| 30 Jun 21 | 1 | 0 | 2 | 0 |
| 30 Sep 20 | 2 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
Ingresos de calidad: 8G8 is currently unprofitable.
Margen de beneficios creciente: 8G8 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 8G8 is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Acelerando crecimiento: Unable to compare 8G8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 8G8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rentabilidad financiera
Alta ROE: 8G8 has a negative Return on Equity (-676.93%), as it is currently unprofitable.